Dual targeting strategies with bispecific antibodies
TLDR
This review discusses the various dual targeting strategies for which bispecific antibodies have been developed and provides an overview of the established bispespecific antibody formats.Abstract:
Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and involve redundant or synergistic action of disease mediators or upregulation of different receptors, including crosstalk between their signaling networks. Consequently, blockade of multiple, different pathological factors and pathways may result in improved therapeutic efficacy. This result can be achieved by combining different drugs, or use of the dual targeting strategies applying bispecific antibodies that have emerged as an alternative to combination therapy. This review discusses the various dual targeting strategies for which bispecific antibodies have been developed and provides an overview of the established bispecific antibody formats.read more
Citations
More filters
Journal ArticleDOI
The making of bispecific antibodies
TL;DR: There is not ‘one best format’ for generating bispecific antibodies, and no single format is suitable for all, or even most of, the desired applications, but the bispespecific formats collectively serve as a valuable source of diversity that can be applied to the development of therapeutics for various indications.
Journal ArticleDOI
Alternative molecular formats and therapeutic applications for bispecific antibodies.
TL;DR: Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described and provide great opportunity to tailor the design of bispecific antibody to match the proposed mechanisms of action and the intended clinical application.
Journal ArticleDOI
Characterization of Therapeutic Antibodies and Related Products
Journal ArticleDOI
Deciphering and reversing tumor immune suppression.
TL;DR: The ways in which tumors exert immune suppression are reviewed and the new therapies that seek to reverse this phenomenon and promote anti-tumor immunity are highlighted.
Journal ArticleDOI
Tetraspanin proteins promote multiple cancer stages
TL;DR: New studies that have used de novo mouse cancer models to show that select tetraspanin proteins have key roles in tumour initiation, promotion and metastasis are emphasized.
References
More filters
Journal ArticleDOI
Angiogenesis in cancer and other diseases
Peter Carmeliet,Rakesh K. Jain +1 more
TL;DR: Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases and integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases, but owing to several unanswered questions, caution is needed.
Journal ArticleDOI
Nanocarriers as an emerging platform for cancer therapy
Dan Peer,Jeffrey M. Karp,Jeffrey M. Karp,Seungpyo Hong,Omid C. Farokhzad,Rimona Margalit,Robert Langer +6 more
TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Journal ArticleDOI
Vascular endothelial growth factor: basic science and clinical progress.
TL;DR: Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models and is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.
Journal ArticleDOI
Therapeutic Nanoparticles for Drug Delivery in Cancer
TL;DR: In this paper, the authors proposed a passive targeting mechanism, active targeting strategies using ligands or antibodies directed against selected tumor targets amplify the specificity of these therapeutic nanoparticles, enabling them to carry their loaded active drugs to cancer cells by selectively using the unique pathophysiology of tumors.
Journal Article
Therapeutic Nanoparticles for Drug Delivery in Cancer
TL;DR: Multifunctional and multiplex nanoparticles are now being actively investigated and are on the horizon as the next generation of nanoparticles, facilitating personalized and tailored cancer treatment.
Related Papers (5)
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Alternative molecular formats and therapeutic applications for bispecific antibodies.
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou,Eugen Leo,Gerhard Zugmaier,Matthias Klinger,Mariele Goebeler,Stefan Knop,Richard Noppeney,Andreas Viardot,Georg Hess,Martin Schuler,Hermann Einsele,Christian Brandl,Andreas Wolf,Petra Kirchinger,Petra Klappers,Margit Schmidt,Gert Riethmüller,Carsten Reinhardt,Patrick A. Baeuerle,Peter Kufer +19 more